NLS Pharmaceutics, which is developing controlled-release formulations of approved drugs for ADHD and narcolepsy, filed on Tuesday with the SEC to raise up to $40 million in an initial public offering ...
In addition, NLS Pharmaceutics provided unaudited pro forma condensed combined financial statements for the six months ended June 30, 2025. According to the previously announced merger agreement, ...
The company will not receive any proceeds from the sale of the common shares by the selling shareholders. Published first on TheFly – the ultimate source for real-time, market-moving breaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback